S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

FibroGen Stock Forecast, Price & News

+0.17 (+0.39 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $43.23
50-Day Range
MA: $40.33
52-Week Range
Now: $43.23
Volume1.75 million shs
Average Volume764,536 shs
Market Capitalization$3.93 billion
P/E RatioN/A
Dividend YieldN/A
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen logo


Overall MarketRank

1.59 out of 5 stars

Medical Sector

261st out of 1,558 stocks

Pharmaceutical Preparations Industry

139th out of 638 stocks

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FGEN



Sales & Book Value

Annual Sales$256.58 million
Book Value$6.14 per share


Net Income$-76,970,000.00
Net Margins-191.78%


Market Cap$3.93 billion
Next Earnings Date3/1/2021 (Estimated)
+0.17 (+0.39 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

How has FibroGen's stock been impacted by Coronavirus (COVID-19)?

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FGEN stock has increased by 22.1% and is now trading at $43.23.
View which stocks have been most impacted by COVID-19

Is FibroGen a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FibroGen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View analyst ratings for FibroGen
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than FibroGen?

Wall Street analysts have given FibroGen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but FibroGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is FibroGen's next earnings date?

FibroGen is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for FibroGen

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Thursday, November, 5th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.80) by $1.15. The biopharmaceutical company earned $44.03 million during the quarter, compared to analyst estimates of $61.49 million. FibroGen had a negative net margin of 191.78% and a negative return on equity of 48.19%. FibroGen's quarterly revenue was up 32.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.57) earnings per share.
View FibroGen's earnings history

What price target have analysts set for FGEN?

6 equities research analysts have issued 1 year price targets for FibroGen's stock. Their forecasts range from $40.00 to $92.00. On average, they expect FibroGen's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price.
View analysts' price targets for FibroGen
or view Wall Street analyst' top-rated stocks.

Who are some of FibroGen's key competitors?

What other stocks do shareholders of FibroGen own?

Who are FibroGen's key executives?

FibroGen's management team includes the following people:
  • Mr. James A. Schoeneck, Chairman (Age 62, Pay $751.63k)
  • Mr. Pat Cotroneo, Chief Financial Officer (Age 56, Pay $773.57k)
  • Dr. K. Peony Yu, Exec. Advisor to Chief Exec. Officer (Age 58, Pay $926.21k)
  • Dr. Elias Kouchakji, Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance (Age 64, Pay $863.19k)
  • Ms. Christine L. Chung, Sr. VP of China Operations (Age 52, Pay $701.09k)
  • Mr. Enrique A. Conterno, CEO & Director (Age 53)
  • Dr. Barry A. Berkowitz, Founder
  • Dr. Michael J. Martinelli, Sr. VP of Technical Devel.
  • Dr. Percy Carter M.B.A., Ph.D., Chief Scientific Officer
  • Ms. Karen L. Bergman, VP of Investor Relations & Corp. Communications

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Polianta Ltd (0.03%) and Sowell Financial Services LLC (0.00%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen

Which major investors are buying FibroGen stock?

FGEN stock was acquired by a variety of institutional investors in the last quarter, including Polianta Ltd, and Sowell Financial Services LLC.
View insider buying and selling activity for FibroGen
or or view top insider-buying stocks.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $43.23.

How big of a company is FibroGen?

FibroGen has a market capitalization of $3.93 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 531 workers across the globe.

What is FibroGen's official website?

The official website for FibroGen is www.fibrogen.com.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.